On this page
Quick Reference
Overview and Recommendations
Background
- •Esophageal cancer surveillance after curative-intent treatment (esophagectomy, definitive chemoradiotherapy, or endoscopic resection) aims to detect locoregional and distant recurrence, manage treatment-related late toxicities, and identify second primary malignancies. Recurrence occurs in approximately of patients, with a median time to recurrence of 7-12 months. The majority of recurrences (81.8%) occur within the first 5 years, making structured follow-up critical during this window.
- •The risk of recurrence is stratified by histopathologic and treatment-related factors. Deep submucosal invasion (SM2), non-curative resection, positive margins, lymphovascular invasion, and grade 3 differentiation are high-risk features. Prior esophageal cancer history increases the hazard of recurrence-metastasis. A history of also increases neoplastic progression risk.
- •Recurrence patterns vary: after esophagectomy, locoregional recurrence (LRR) occurs in a substantial proportion and carries a median survival of 6-8 months without salvage treatment. Distant metastases are more common in adenocarcinoma. Oligometastatic disease (≤5 distant metastases on PET-CT) is present in 24% of metastatic patients and represents a distinct subgroup where aggressive local therapy plus systemic therapy improves overall survival (HR 0.47, median OS 35 months vs 13 months).
- •Late toxicities affect the majority of survivors. Dumping syndrome (moderate early in 45%, severe in 9% at 1 year), weight loss (mean 8.5% at 6 months), micronutrient deficiencies (iron deficiency in 43-46% pre- and postoperatively), and frailty (prevalence 28% preoperatively, rising to 68% at 1 week postoperatively) are pervasive and impact quality of life. Psychological distress affects both patients and caregivers (30% moderate-high anxiety in caregivers).
- •The optimal surveillance schedule remains debated due to lack of high-level randomized data, but cohort studies and expert consensus support a risk-stratified approach: endoscopy plus CT at 3, 6, and 12 months, then annually for at least 5 years, with biannual intervals for high-risk patients. Brain imaging surveillance is recommended for adenocarcinoma due to higher incidence of brain metastases (5.34% vs 1.45% for squamous cell carcinoma).
Evaluation
- •Suspect recurrent esophageal cancer when a patient reports new or worsening dysphagia, odynophagia, weight loss, or pain. Also consider late toxicity symptoms such as postprandial diaphoresis, palpitations, diarrhea (dumping syndrome), heartburn/regurgitation (reflux), or respiratory symptoms (cough, fever, purulent sputum) indicating possible anastomotic stricture, aspiration, or pneumonia.
- •At each clinic visit, perform a focused history and physical examination. Ask about dysphagia, odynophagia, weight loss, dumping symptoms, reflux, and respiratory symptoms. For patients on immune checkpoint inhibitors, inquire about rash, diarrhea, pneumonitis symptoms, or endocrinopathies (irAEs occur in 28% and are associated with improved progression-free survival).
- •Examine for signs of recurrence: palpable supraclavicular or cervical lymph nodes, abdominal mass, ascites, jaundice, or pleural effusion. Assess nutritional status (weight, BMI, muscle wasting). Evaluate for signs of dumping (tachycardia, diaphoresis) or reflux (regurgitation, cough). Perform a frailty assessment using tools such as the Modified Frailty Index.
- •Order computed tomography (CT) of the chest and abdomen with contrast as the primary imaging modality for surveillance. CT detects locoregional and distant recurrence. For patients with adenocarcinoma, consider brain MRI or CT for neuroimaging surveillance at staging and follow-up due to higher brain metastasis risk (5.34%).
- •Perform endoscopy with high-definition white-light and narrow-band imaging to assess the anastomotic site, residual esophagus, and gastric conduit. Endoscopy is the gold standard for detecting local recurrence. Obtain biopsy confirmation of any suspicious lesions. For patients after endoscopic resection, post-endoscopy esophageal advanced lesions (PEEALs) occur in and are often small (median 10 mm) with marginal elevation morphology.
- •Measure tumor markers (carcinoembryonic antigen, squamous cell carcinoma antigen) if initially elevated, though routine use is not universally recommended. Their value lies in trend monitoring, not diagnosis.
- •Diagnostic criteria for recurrence include biopsy-proven local recurrence, or new distant lesions on imaging. For oligometastatic disease, confirm with ¹⁸F-FDG-PET/CT. In patients with prior definitive chemoradiotherapy, endoscopic findings of large tumor size, type 0-I morphology, and B3 vessels signal high risk of non-radical cure and warrant intensified surveillance.
- •Also consider late toxicity evaluation: for dumping syndrome, use a symptom questionnaire (e.g., Sigstad's clinical diagnostic index). For nutritional deficiencies, order serum iron, ferritin, B12, folate, and vitamin D levels. For frailty, use the Modified Frailty Index or the Clinical Frailty Scale. For psychological distress, screen with HADS or similar validated tools.
- •Differential diagnoses for dysphagia after esophagectomy include anastomotic stricture (common), recurrent disease, or functional dysmotility. Stricture is more likely if symptoms occur within weeks to months postoperatively. Recurrence tends to be later and progressive. Endoscopy with biopsy differentiates.
- •When recurrence is suspected, the confirmatory workup includes biopsy for local lesions and PET/CT for staging. Multidisciplinary discussion guides treatment decisions (salvage radiotherapy, chemoradiotherapy, endoscopic resection, or systemic therapy). For oligometastatic disease, local treatment (stereotactic body radiotherapy or metastasectomy) plus systemic therapy improves survival.
Management
- •Implement a structured surveillance schedule: protocol includes endoscopy plus CT (or MRI) and tumor markers at months 3, 6, and 12, then annually for at least 5 years. For high-risk patients (deep submucosal invasion SM2, non-curative resection, positive margins, lymphovascular invasion), intensify to biannual follow-up during years 2-4. Minimum duration of surveillance is 5 years.
- •For patients after salvage radiotherapy for locoregional recurrence, perform PET-CT at 1 month and 3-4 months after RT completion, then clinic visits and chest CT every 3-4 months for the first 2 years, then every 6-12 months thereafter.
- •For patients with adenocarcinoma, include regular brain imaging (CT or MRI) at staging and as part of surveillance follow-up, given the higher incidence of brain metastases (5.34%).
- •Manage dumping syndrome with dietary counselling: small, frequent meals; low simple sugars; avoid concentrated sweets. For refractory cases, consider octreotide 50-100 mcg subcutaneously three times daily before meals. Monitor for weight loss and social function decline. Severe early dumping occurs in 9% and severe late dumping in 5% at 1 year.
- •Address nutritional deficiencies with routine biochemical screening (iron, B12, folate, vitamin D) preoperatively and at follow-up. Target iron deficiency with oral or IV iron supplementation. Provide protein supplementation at 1.2-1.5 g/kg/day. For weight loss >8% at 6 months, refer to a dietitian-led intervention. Consider jejunostomy feeding for patients with significant weight loss or inadequate oral intake.
- •Manage reflux symptoms with proton pump inhibitors (PPI) and lifestyle modifications (elevate head of bed, avoid large meals). Female patients report greater symptom severity. For anastomotic stricture, perform endoscopic dilation. After extensive ESD (>75% circumference), oral corticosteroids (e.g., prednisolone) may reduce stricture rate and require fewer dilation sessions compared to intralesional triamcinolone.
- •Assess and manage frailty in elderly patients. Preoperative frailty prevalence is 28% and rises to 68% at 1 week postoperatively. Implement multimodal prehabilitation (exercise, nutrition, psychosocial support) during neoadjuvant chemotherapy. Postoperative multimodal inpatient rehabilitation (resistance exercises and moderate-to-high intensity aerobic interval training) significantly improves 6-minute walk distance (73.1 m, P<0.001) and chair stand test.
- •Screen for psychological distress in patients using validated tools. Refer to psycho-oncology for Managing Cancer and Living Meaningfully (CALM) intervention, which reduces distress, anxiety, and depression and improves quality of life. Address caregiver burden: 30% report moderate-high anxiety, 10% moderate-high depression. Include caregivers in consultations, provide information on dietary management, and offer peer support.
- •Counsel patients to report new or worsening symptoms promptly: dysphagia, odynophagia, dumping syndrome symptoms, reflux, respiratory symptoms, and immune-related adverse events (irAEs). Emphasize smoking cessation (strong risk factor for postoperative pneumonia), physical activity (30-second chair stand test for prehabilitation), and weight management (higher BMI increases early reflux risk).
- •Avoid routine brain imaging in squamous cell carcinoma unless symptomatic, as incidence is low (1.45%). Avoid using non-dihydropyridine calcium channel blockers for reflux - they are not indicated. Do not rely solely on tumor markers for diagnosis of recurrence; confirm with imaging and biopsy.
- •Refer to a dietitian for persistent weight loss or dumping syndrome. Refer to a gastroenterologist for endoscopic surveillance and management of strictures. Refer to a cardiothoracic surgeon for consideration of salvage therapy if locoregional recurrence is detected. Refer to a psycho-oncologist for psychological distress. Refer to a palliative care specialist for symptom management in advanced disease.
- •Discharge criteria from intensive surveillance: after 5 years without recurrence, the risk diminishes but does not disappear. Ongoing annual surveillance is reasonable, especially for patients with prior high-risk features. For patients who develop recurrence, transition to treatment-focused management. For patients with good quality of life and no recurrence, consider shared decision-making to reduce frequency if patient preferences align.
Board Review — High Yield
- •Dumping syndrome - Affects 45% of survivors at 1 year (moderate early); severe in 9%. Manage with dietary changes and octreotide if refractory.
- •Recurrence risk factors - Deep submucosal invasion (SM2), non-curative resection, positive margins, lymphovascular invasion, grade 3 differentiation, piecemeal resection.
- •Surveillance schedule - Endoscopy + CT at 3, 6, 12 months, then annually for 5 years. High-risk: biannual years 2-4.
- •Brain metastases - More common in adenocarcinoma (5.34%) vs squamous cell (1.45%); regular brain imaging recommended for adenocarcinoma.
- •Oligometastatic disease - ≤5 metastases on PET-CT; local therapy (SBRT/metastasectomy) + systemic therapy improves OS (HR 0.47).
- •Frailty - Preoperative prevalence 28%, rises to 68% at 1 week postop. Multimodal prehabilitation and rehabilitation improve outcomes.
- •Nutritional deficiencies - Iron deficiency most common (43% preop, 45% postop); screen for iron, B12, folate, vitamin D; supplement as needed.
- •Immune-related adverse events - Occur in 28% of patients on checkpoint inhibitors; associated with better PFS; counsel patients to report promptly.
- •Post-endoscopy advanced lesions - rate; small (median 10 mm), marginal elevation; use high-definition white-light and NBI.
- •Caregiver burden - 30% moderate-high anxiety, 10% depression; include caregivers in consultations and provide support.
Deep Dive — Evidence Details
Surveillance Schedule
- ▸Surveillance after curative treatment for esophageal cancer should include clinic visits, imaging (CT/PET-CT), endoscopy, and tumor markers, with a protocol of endoscopy + CT + tumor markers at 3, 6, 12 months, then annually for at least 5 years.
- ▸High-risk patients (deep submucosal invasion, non-curative resection, prior esophageal cancer) require more intensive follow-up, including biannual surveillance in the first 2-4 years [16].
- ▸Brain imaging surveillance is supported for patients with adenocarcinoma, given the higher incidence of brain metastases (5.34% vs 1.45% in squamous cell carcinoma) [14].
Surveillance after curative-intent treatment for aims to detect recurrent disease, manage late complications, and identify second primary malignancies. The optimal schedule remains debated, but the available evidence from longitudinal studies provides a framework for risk-stratified follow-up.
Components of Surveillance
The follow-up protocol should include the following elements:
- Clinic visits with history and physical examination, focusing on symptoms of recurrence (dysphagia, weight loss, pain) and late toxicity ( , anastomotic stricture, nutritional deficiencies).
- Imaging with computed tomography (CT) of the chest and abdomen, with or without PET-CT, to evaluate for locoregional and distant recurrence.
- Endoscopy to assess the anastomotic site, residual esophagus, and gastric conduit for local recurrence and metachronous lesions.
- Tumor markers (e.g., carcinoembryonic antigen, squamous cell carcinoma antigen) when initially elevated, though their routine use is not universally recommended.
Evidence-Based Schedule
A standardized protocol described in a cohort study of patients undergoing endoscopic submucosal dissection (ESD) for early esophageal neoplasia included the following schedule [16]B3b:
- Months 3, 6, and 12: Endoscopy plus CT (or magnetic resonance imaging) and tumor markers.
- Annually thereafter (or biannually for high-risk patients, defined as those with deep submucosal invasion [SM2] or non-curative resection [NCR]).
- Minimum duration of surveillance: 5 years, with intensified surveillance during the first 2-4 years [16]B3b.
For patients who develop locoregional recurrence after and undergo salvage radiotherapy, the follow-up schedule is more intensive [20]C4:
- 1 month after RT completion: First response evaluation, typically with PET-CT.
- 3-4 months thereafter: Second response evaluation, again with PET-CT.
- For the first 2 years: Clinic visits and chest CT (with or without abdomen-pelvis CT) every 3-4 months.
- Thereafter: Visits every 6-12 months.
Risk Stratification and Duration
The intensity of surveillance should be tailored to the risk of recurrence. The evidence identifies several factors that warrant more frequent follow-up [16]B3b:
- High-risk histology: Deep submucosal invasion (SM2), non-curative resection, positive margins, lymphovascular invasion.
- Prior esophageal cancer: A history of previous esophageal malignancy increases the risk of second primary tumors and recurrence (HR 3.05 for disease-free survival, HR 18.23 for recurrence-metastasis) [16]B3b.
- Older age: Each additional year of age increases the hazard of recurrence by 1.8% [16]B3b.
The recommended minimum follow-up period is 5 years, as [16]B3b. After 5 years, the risk diminishes but does not disappear, and ongoing annual surveillance is reasonable, particularly for patients with prior high-risk features.
Brain Imaging Surveillance
Although from esophageal cancer are uncommon (pooled incidence 2.84%), they carry a poor prognosis (median survival 5.62 months) and are more frequent in adenocarcinoma (5.34%) than squamous cell carcinoma (1.45%) [14]B2a. The evidence supports "regular use of brain imaging at staging and neuroimaging surveillance at follow-up" in patients with esophageal carcinoma, particularly those with adenocarcinoma or symptoms suggestive of central nervous system involvement [14]B2a.
Surveillance After Endoscopic Resection
For patients treated with endoscopic resection alone (e.g., ESD or ), the schedule includes endoscopy at 3, 6, and 12 months, then annually, as described above [16]B3b. The risk of post-endoscopy esophageal advanced lesions (PEEALs), defined as subsequent ESCC invading the muscularis mucosa or deeper detected within 24 months of previous endoscopy, is approximately 6.5% (20 of 307 lesions) [17]B3b. These lesions are often small (median 10 mm) and exhibit a marginal elevation morphology, underscoring the need for careful endoscopic surveillance with high-definition white-light and narrow-band imaging [17]B3b.
Summary of Surveillance Schedule
| Time Point | Components | Frequency |
|---|---|---|
| Months 3, 6, 12 | Endoscopy, CT/MRI, tumor markers | Three visits in first year |
| Years 2-4 | Clinic visit, chest CT, ± endoscopy | Every 6-12 months (high-risk: every 6 months) |
| Years 5+ | Clinic visit, chest CT, ± endoscopy | Annually |
| After salvage RT | PET-CT at 1 month and 3-4 months, then CT every 3-4 months for 2 years, then every 6-12 months | See [20]C4 |
The evidence for this schedule is derived from cohort studies and expert consensus; high-level randomized data are lacking. Clinicians should individualize follow-up based on recurrence risk, patient preferences, and institutional resources.
Pearl: The most common surveillance schedule is endoscopy + CT + tumor markers at 3, 6, and 12 months post-treatment, then annually for at least 5 years, with biannual follow-up reserved for high-risk patients (SM2 invasion or non-curative resection) [16]B3b.
Detection of Recurrence
- ▸Oligometastatic disease (≤5 metastases) is present in 24% of metastatic patients and may benefit from local ablative therapy combined with systemic therapy.
- ▸Endoscopic features (large size, type 0-I, B3 vessels) and radiomics models can identify patients at high risk for recurrence after definitive CRT or trimodal therapy.
The surveillance schedule provides the framework, but the actual detection of recurrence depends on the interplay between scheduled imaging, endoscopic surveillance, and symptom-triggered evaluation. Understanding recurrence patterns, risk factors, and the performance of detection modalities is essential for timely diagnosis and optimal salvage therapy.
Patterns of Recurrence
After initial , **42.5% to ** of patients experience disease recurrence, with a median time to recurrence of 7.0 to 12.2 months [20]C4. Loco-regional recurrence (LRR) occurs in a substantial proportion and carries a more favorable prognosis than distant metastasis; median survival after LRR is 6.0 to 8.2 months without salvage treatment [20]C4. In a large salvage radiotherapy series, recurrence was local in 16.3%, regional in 72.8%, and both in 10.9% [20]C4. After definitive chemoradiotherapy (CRT), local residual disease or recurrence remains a concern, particularly for tumors with high-risk endoscopic features [32]C4. Oligometastatic disease (OMD), defined as ≤5 distant metastases on ¹⁸F-FDG-PET/CT, is present in 24% of patients with metastatic esophagogastric cancer and represents a distinct subgroup where aggressive local therapy may confer a survival benefit [13]A1b.
Risk Factors for Recurrence
Several tumor- and patient-related factors predict recurrence. In endoscopically resected patients, grade 3 differentiation and piecemeal resection independently predict local recurrence, while lymphovascular invasion predicts lymph node positivity [21]C4. For cT1bN0M0 esophageal squamous cell carcinoma (ESCC) treated with definitive CRT, endoscopic findings of large tumor size, type 0-I morphology, and B3 vessels are associated with a high risk of non-radical cure [32]C4. A combined model integrating contrast-enhanced CT radiomics and clinical features predicted early recurrence (within 1 year) after trimodal therapy with an AUC of 0.809 in the validation cohort [24]A1b. Chronic esophageal inflammation, as seen in , increases the risk of neoplastic progression and warrants careful endoscopic surveillance [35]C4.
Modalities for Detection
Endoscopy remains the gold standard for detecting local recurrence. Biopsy confirmation should be obtained whenever feasible [20]C4. Emerging minimally invasive tools, such as the capsule-sponge device with p53 immunohistochemistry, show promise for detecting esophageal squamous neoplasia, with an accuracy of 94.2% and specificity of 95.4% in a case-enriched cohort [22]C4. Diffusion-weighted MRI can serve as a biomarker for early treatment response; ADC values at weeks 2-3 of CRT are highly predictive of eventual tumor response, and a plateau in ADC increase may signal a high risk of recurrence within 1 year [23]C4. ¹⁸F-FDG-PET/CT is routinely used for staging at recurrence and was performed in 84.3% of patients in a large salvage series [20]C4.
Symptom-Triggered Evaluation
New or worsening dysphagia, odynophagia, weight loss, or pain should prompt immediate endoscopic and imaging evaluation. However, many recurrences are detected on scheduled surveillance before symptoms develop, underscoring the importance of adherence to the surveillance schedule.
Hand-off to Confirmatory Workup
Once recurrence is suspected, confirmatory workup includes biopsy for local lesions and PET/CT for staging. Multidisciplinary discussion guides treatment decisions, which may include salvage radiotherapy, chemoradiotherapy, endoscopic resection, or systemic therapy. For oligometastatic disease, local treatment ( or metastasectomy) combined with systemic therapy is independently associated with improved overall survival (HR 0.47; median OS 35 months vs 13 months with systemic therapy alone) [13]A1b.
Pearl: The strongest predictor of local recurrence after endoscopic resection is grade 3 differentiation and piecemeal resection; for definitive CRT, type 0-I morphology with B3 vessels signals high risk of non-radical cure, these patients warrant intensified surveillance and early consideration of salvage therapy.
| Primary Treatment | Recurrence Rate | Median Time to Recurrence | Common Patterns |
|---|---|---|---|
| Esophagectomy | 42.5-52.4% [20]C4 | 7.0-12.2 months [20]C4 | Loco-regional (72.8% regional, 16.3% local) [20]C4 |
| Definitive CRT (cT1bN0M0) | Variable; high risk with type 0-I, B3 vessels [32]C4 | Not specified | Local residual/recurrence [32]C4 |
| Neoadjuvant therapy + surgery | 16.8% never reach surgery; 43.9% due to progression [36]C4 | During neoadjuvant period | Distant progression, irresectability [36]C4 |
| Endoscopic resection (T1a) | Local recurrence 0-17% [21]C4 | Variable | Local (predicted by grade 3, piecemeal) [21]C4 |
Late Toxicity and Survivorship
Once recurrence is ruled out, the focus shifts to managing the long-term consequences of treatment. and multimodal therapy leave survivors with a constellation of persistent symptoms, nutritional deficits, functional decline, and psychological distress that require structured, multidisciplinary follow-up.
Dumping syndrome is a common and underrecognized complication after esophagectomy. In a prospective cohort of 188 patients one year after surgery, 45% experienced moderate early dumping symptoms and 9% reported severe early dumping; moderate late dumping occurred in 13% and severe late dumping in 5% [38]B2b. Severe early dumping was associated with clinically large reductions in global quality of life (mean difference -16, 95% CI -27 to -4) and social function (mean difference -17, 95% CI -32 to -3) [38]B2b. Severe late dumping significantly impaired cognitive function (mean difference -27, 95% CI -47 to -7) and emotional function (mean difference -24, 95% CI -47 to -2) [38]B2b. Dietary counselling and medical support are essential to alleviate these symptoms [38]B2b. In a dedicated survivorship clinic, 70.3% of patients had clinically significant dumping persisting to 12 months after surgery [50]D5.
Nutritional Deficiencies and Weight Loss
Weight loss and micronutrient deficiencies are pervasive. In a cohort of 75 patients followed in a nutrition and survivorship clinic, mean body weight loss was 8.5% at 6 months and 8.8% at 12 months [50]D5. Micronutrient deficiency was present in 79.4% preoperatively and 80.6% at 12 months (P = 0.727), most commonly iron deficiency (preoperative 43.2%, postoperative 45.9%) [50]D5. Routine biochemical screening for iron, B12, folate, and vitamin D is warranted. Nutritional support techniques influence patient-reported outcomes: among patients undergoing esophagectomy, jejunostomy may be associated with higher quality-of-life scores and less postoperative pain compared with nasojejunal tubes [40]B2a. For patients receiving palliative care, expandable metal stents (SEMS) were associated with higher emotional functioning than laparoscopic gastrostomy [40]B2a.
Frailty and Functional Decline
Frailty is highly prevalent and predicts worse recovery. In a prospective study of 131 elderly patients undergoing esophagectomy, 28.2% were frail before surgery; the prevalence rose to 67.9% at 1 week postoperatively and remained elevated at 3 months (39.7%) [43]B3b. Preoperatively frail patients had significantly worse global quality of life (β = -4.24, 95% CI -8.31 to -0.18), physical functioning (β = -9.87, 95% CI -14.59 to -5.16), role functioning (β = -10.04, 95% CI -15.76 to -4.33), and social functioning (β = -8.58, 95% CI -15.49 to -1.68) compared with non-frail patients [43]B3b. Frailty assessment using tools such as the Modified Frailty Index is feasible in the preoperative outpatient setting and may help identify vulnerable patients [45]C4.
Multimodal prehabilitation, combining exercise, nutrition, and psychosocial support, is feasible during neoadjuvant chemotherapy. In a randomized feasibility trial, both supervised hospital-based and home-based programs maintained cardiorespiratory fitness and improved functional capacity and quality of life [39]C4. A 12-week walking and dietary education program improved rest/activity circadian rhythm and total sleep time in survivors [4]A1b. Early postoperative multimodal inpatient rehabilitation (resistance exercises and moderate- to high-intensity aerobic interval training) significantly improved 6-minute walk distance (73.1 vs 28.4 m, P < 0.001, d = 1.15) and 30-second chair stand test (3.5 vs 0.35 repetitions, P < 0.001, d = 1.06) compared with conventional pulmonary rehabilitation alone [41]B3b.
Psychological Distress and Caregiver Burden
Psychological distress is common in both survivors and their informal caregivers. The Managing Cancer and Living Meaningfully (CALM) intervention significantly reduced psychological distress, anxiety, and depression and improved quality of life in esophageal cancer patients, with effects sustained at 1 month [51]D5. Caregivers of upper gastrointestinal cancer patients experience substantial burden: 30% report moderate-to-high anxiety and 10% report moderate-to-high depression, alongside significant fear of recurrence [37]B2a. Caregivers often feel unprepared, excluded from medical settings, and struggle with dietary management and social isolation [37]B2a. Addressing caregiver needs as co-clients is critical.
Patient Preferences and Shared Decision-Making
Understanding patient preferences is essential for tailoring survivorship care. In a discrete choice experiment among 149 Japanese patients with esophageal cancer, the most important attribute for treatment preferences was 1-year overall survival (relative attribute importance 31.4%), followed by hospitalization/dosing time (27.3%) [52]D5. Patients were willing to trade a 17.4% reduction in 1-year survival to avoid hospitalization and long infusion times [52]D5. Patients aged ≥65 years prioritized quality of life over survival more than younger patients [52]D5. These findings underscore the need for shared decision-making that aligns treatment intensity with individual values.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Dumping syndrome (early moderate) | 45% at 1 year [38]B2b | Dietary counselling, small frequent meals, low simple sugars [38]B2b | Medical support, dietary modification, consider octreotide if refractory [38]B2b |
| Dumping syndrome (severe early) | 9% at 1 year [38]B2b | As above | As above; monitor for weight loss and social function decline [38]B2b |
| Weight loss >8% | 8.5% at 6 months, 8.8% at 12 months [50]D5 | Preoperative nutrition optimization, jejunostomy feeding [40]B2a | Dietitian-led intervention, protein supplementation (1.2-1.5 g/kg/day) [39]C4 |
| Micronutrient deficiency | 80.6% at 12 months (most commonly iron) [50]D5 | Routine biochemical screening pre- and postoperatively [50]D5 | Targeted supplementation (iron, B12, folate, vitamin D) [50]D5 |
| Frailty | 28.2% preoperatively, 67.9% at 1 week [43]B3b | Preoperative frailty assessment, prehabilitation [39]C4[45]C4 | Multimodal rehabilitation (exercise, nutrition, psychosocial) [39]C4[41]B3b |
| Psychological distress (patient) | Not specified; CALM intervention effective [51]D5 | Routine screening with HADS or similar [39]C4 | CALM therapy, referral to psycho-oncology [51]D5 |
| Caregiver anxiety (moderate-high) | 30% [37]B2a | Include caregivers in consultations, provide information [37]B2a | Peer support, psychoeducation, dietician-led interventions [37]B2a |
| Caregiver depression (moderate-high) | 10% [37]B2a | As above | As above; address fear of recurrence [37]B2a |
Pearl: Dumping syndrome and micronutrient deficiencies affect the majority of esophageal cancer survivors at 1 year; routine screening and dietary counselling should be standard components of survivorship care, not afterthoughts.
Patient Counselling
- ▸Dumping syndrome affects 78% of esophagectomy survivors; structured symptom assessment at each visit is essential.
- ▸Reflux risk is higher in patients with distal tumors, higher BMI, and female sex; early dietary counselling and proton pump inhibitor therapy may mitigate symptoms.
- ▸Immune-related adverse events occur in 28% of ICI-treated patients and are independently associated with improved survival, warranting patient education and prompt reporting.
The previous section detailed late toxicities. The following addresses patient counselling across follow-up, equipping survivors to recognize early warning signs and adopt practices that mitigate complications and preserve quality of life.
Symptoms to Report at Each Visit
Patients should be explicitly instructed to report any new or worsening symptoms between scheduled visits. The most common and clinically significant include:
- - symptoms such as postprandial diaphoresis, palpitations, diarrhea, and early satiety. Dumping syndrome occurs in 78% of patients after at least once during follow-up, with a point prevalence of 40-45% at individual visits [11]B2b. Male sex triples the odds (adjusted OR 3.04, 95% CI 1.11-8.17) [11]B2b.
- Reflux symptoms - heartburn, regurgitation, and nocturnal cough. Distal or gastroesophageal junction tumors and higher BMI increase early reflux risk, while neoadjuvant therapy, older age, and a longer oral-to-solid diet interval are protective [66]B3b. Female patients report greater symptom severity [66]B3b.
- Dysphagia or odynophagia - may indicate anastomotic stricture or recurrent disease. After extensive endoscopic submucosal dissection (ESD) involving >75% of the circumference, stricture rates are similar whether oral corticosteroids (66.7%) or intralesional triamcinolone (40%) are used (P = 0.27), but oral corticosteroids require fewer dilation sessions (5 vs. 19, P = 0.04) [59]A1b.
- Respiratory symptoms - cough, fever, or purulent sputum. Postoperative pneumonia rates range from 2.0% to 61.5% across studies, with the strongest preoperative predictors being physical frailty (OR 5.17, 95% CI 2.43-11.02), sarcopenia (OR 2.79, 95% CI 1.60-4.86), and low forced expiratory volume (OR 2.73, 95% CI 1.50-4.96) [64]B2a.
- Immune-related adverse events (irAEs) - for patients receiving immune checkpoint inhibitors, irAEs occur in 28% of patients; their presence is independently associated with improved progression-free survival (P = 0.003) [29]C4. Patients should be counselled to report rash, diarrhea, pneumonitis symptoms, or endocrinopathies promptly.
Lifestyle and Supportive Measures
- Diet and nutrition - small, frequent meals; avoidance of concentrated sweets to reduce dumping symptoms. Both groups in the dumping syndrome cohort experienced postoperative weight loss, with a nonsignificant trend toward greater loss in patients with dumping [11]B2b.
- Smoking cessation - smoking is a very strong risk factor for postoperative pneumonia (≥10 significant studies, >50% of all studies) [64]B2a. Referral to cessation programs is essential.
- Physical activity - the 30-second chair stand test (CS-30) is more feasible than the 6-minute walk test and significantly improves prediction of postoperative pulmonary complications [65]B3b. A perioperative exercise program may reduce risk.
- Weight management - higher BMI increases early reflux risk [66]B3b. Overweight patients should receive dietary counselling to mitigate reflux.
Quality of Life Expectations
Longitudinal health-related quality of life (HRQoL) profiles from a nationwide cohort show that 65% of patients have stable-high HRQoL, while 14% deteriorate and 6% fluctuate [62]B2b. Female sex and lower BMI are associated with poorer HRQoL [62]B2b. Clinicians should set realistic expectations and proactively screen for impairments using validated instruments (e.g., EORTC QLQ-C30, QLQ-OG25).
Screening of Family Members
No evidence in the retrieved literature addresses routine screening of family members for HPV-related cancers in the context of surveillance. If HPV-associated esophageal squamous cell carcinoma is suspected, clinicians should follow local public health guidelines for HPV-related in at-risk populations.
Pearl: At every follow-up, a structured symptom inquiry for dumping, reflux, dysphagia, and respiratory symptoms, combined with proactive lifestyle counselling on diet, smoking cessation, and exercise, can identify complications early and improve long-term quality of life in esophageal cancer survivors.
Related Pages
Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
- Esophageal Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
- Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
- Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease
Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Rubenstein JH, Sawas T, Wani S et al.. “AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.” Gastroenterology (2024). PMID: 38763697 ↗
L1GUIDELINECited in: Surveillance Schedule - [2]
Lin Y, Wang H, Qu Y et al.. “Occurrence of Dumping Syndrome After Esophageal Cancer Surgery: Systematic Review and Meta-analysis.” Annals of surgical oncology (2024). PMID: 39068325 ↗
L1SR_MA_RCTCited in: Surveillance Schedule - [3]
Kato K, Kojima T, Hara H et al.. “First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.” Esophagus : official journal of the Japan Esophageal Society (2026). PMID: 42047965 ↗
L1RCTCited in: Surveillance Schedule, Patient Counselling - [4]
Chen HM, Huang CS, Wu YC et al.. “The effects of a 3-month walking and dietary education program on the quality of life of patients with esophageal cancer: a 1-year follow-up randomized controlled trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 40312569 ↗
L1RCTCited in: Surveillance Schedule, Late Toxicity and Survivorship - [5]
Gyldenholm T, Madsen N, Katballe N et al.. “Prolonged vs standard thromboprophylaxis in patients with esophageal cancer undergoing surgery: a randomized controlled study.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 39842514 ↗
L1RCTCited in: Surveillance Schedule - [6]
Xue W, Valderrama A, Ramakrishnan K et al.. “Event-free survival as a surrogate for overall survival in locally advanced esophageal cancer: a correlation analysis of trials assessing definitive chemoradiation therapies.” BMC cancer (2026). PMID: 41963862 ↗
L1SR_MA_RCTCited in: Surveillance Schedule, Patient Counselling - [7]
Park A, Orlandini MF, Szor DJ et al.. “The impact of sarcopenia on esophagectomy for cancer: a systematic review and meta-analysis.” BMC surgery (2023). PMID: 37592262 ↗
L2SR_COHORTCited in: Surveillance Schedule - [8]
Lin N, Lin J, Gong J. “Risk factors of postoperative stricture after endoscopic submucosal dissection for superficial esophageal neoplasms: A meta-analysis.” Medicine (2021). PMID: 34941174 ↗
L2SR_COHORTCited in: Surveillance Schedule - [9]
Okui J, Matsuda S, Nagashima K et al.. “Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials.” Annals of surgery (2025). PMID: 40853558 ↗
L2NON_RANDOMIZED_TRIALCited in: Surveillance Schedule - [10]
Sijben J, Peters Y, van der Velden K et al.. “Public acceptance and uptake of oesophageal adenocarcinoma screening strategies: A mixed-methods systematic review.” EClinicalMedicine (2022). PMID: 35399814 ↗
L2SR_COHORTCited in: Surveillance Schedule, Detection of Recurrence - [11]
Axelgaard I, Mucha AW, Nerup NA et al.. “Dumping Syndrome After Esophagectomy: Prevalence and Predictors in Gastroesophageal Cancer Patients.” The Journal of surgical research (2026). PMID: 42139856 ↗
L2PROSPECTIVE_COHORTCited in: Surveillance Schedule, Patient Counselling - [12]
Rubenstein JH. “Surveillance in Barrett's Esophagus: Utility and Current Recommendations.” Gastroenterology clinics of North America (2015). PMID: 26021195 ↗
L5NARRATIVE_REVIEWCited in: Surveillance Schedule - [13]
Kroese TE, Christ SM, van Rossum PSN et al.. “Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2022). PMID: 35753555 ↗
L1RCTCited in: Surveillance Schedule, Detection of Recurrence - [14]
Hong H, Ding J, Yuan C et al.. “Incidence and prognosis of brain metastases in esophageal carcinoma: a systematic review and meta-analysis.” Journal of thoracic disease (2025). PMID: 41229813 ↗
L2SR_COHORTCited in: Surveillance Schedule, Patient Counselling - [15]
Kang YW, Son M, Lee JY et al.. “Subtype-specific associations of steatotic liver disease with gastric and esophageal cancers: a nationwide cohort study.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 41528661 ↗
L3COHORTCited in: Surveillance Schedule - [16]
Zhang YM, Zhu N, Chen MY et al.. “Clinical features of early esophageal neoplastic lesions at different stages and efficacy and prognosis after endoscopic submucosal dissection.” World journal of gastroenterology (2025). PMID: 41112011 ↗
L3COHORTCited in: Surveillance Schedule - [17]
Kitagawa D, Ishihara R, Yoshii S et al.. “Post-endoscopy esophageal squamous cell carcinoma with invasion of the muscularis mucosa or deeper detected in surveillance endoscopy after esophageal endoscopic resection.” Esophagus : official journal of the Japan Esophageal Society (2025). PMID: 40186821 ↗
L3COHORTCited in: Surveillance Schedule - [18]
Tang X, Meng QQ, Gao Y et al.. “Long-term Outcomes of Endoscopic Radiofrequency Ablation versus Endoscopic Submucosal Dissection for Widespread Superficial Esophageal Squamous Cell Neoplasia.” Gut and liver (2025). PMID: 39778880 ↗
L3COHORTCited in: Surveillance Schedule, Detection of Recurrence - [19]
Pakneshan S, Moy N, Shah A et al.. “Post-colonoscopy upper gastrointestinal malignancies in positive immunochemical fecal occult blood test patients: An Australian data linkage study.” Journal of gastroenterology and hepatology (2024). PMID: 39503334 ↗
L3COHORTCited in: Surveillance Schedule - [20]
Cho WK, Noh JM, Oh D et al.. “Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following Surgery.” Cancer research and treatment (2024). PMID: 39054622 ↗
L4COHORTCited in: Surveillance Schedule, Detection of Recurrence - [21]
Sgourakis G, Gockel I, Lang H. “Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.” World journal of gastroenterology (2013). PMID: 23539431 ↗
L4SR_COHORTCited in: Detection of Recurrence - [22]
Turkot MH, Yusuf A, Nowicki-Osuch K et al.. “Feasibility and Diagnostic Accuracy of a Capsule-sponge Device for Esophageal Squamous Neoplasia (EDEN Trial).” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41628756 ↗
L4PROSPECTIVE_COHORTCited in: Detection of Recurrence, Patient Counselling - [23]
Wang L, Liu L, Han C et al.. “The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2016). PMID: 27838148 ↗
L4PROSPECTIVE_COHORTCited in: Detection of Recurrence - [24]
Tang S, Ou J, Liu J et al.. “Application of contrast-enhanced CT radiomics in prediction of early recurrence of locally advanced oesophageal squamous cell carcinoma after trimodal therapy.” Cancer imaging : the official publication of the International Cancer Imaging Society (2021). PMID: 34039403 ↗
L1RCTCited in: Detection of Recurrence - [25]
Anyaduba UL, Orababa OQ, Faye Z et al.. “Meta-Analysis of Recurrence-Free Survival or Disease-Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials.” Cancer reports (Hoboken, N.J.) (2025). PMID: 40387359 ↗
L2SR_COHORTCited in: Detection of Recurrence - [26]
Choe SI, Lee Y, Habashi R et al.. “The role of brachytherapy in treatment of stage I esophageal cancer: A systematic review.” Brachytherapy (2022). PMID: 35941072 ↗
L2SR_COHORTCited in: Detection of Recurrence - [27]
Liu YZ, Lv XH, Deng K et al.. “Efficacy and safety of endoscopic submucosal tunnel dissection vs endoscopic submucosal dissection for early superficial upper gastrointestinal precancerous lesions and tumors: A meta-analysis.” Journal of digestive diseases (2020). PMID: 32579253 ↗
L2SR_COHORTCited in: Detection of Recurrence - [28]
Xu R, Wang F, Wu L et al.. “A systematic review of hypermethylation of p16 gene in esophageal cancer.” Cancer biomarkers : section A of Disease markers (2013). PMID: 24240582 ↗
L2SR_COHORTCited in: Detection of Recurrence - [29]
Matsui K, Miyawaki Y, Suzuki Y et al.. “Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42001475 ↗
L4RETROSPECTIVE_COHORTCited in: Detection of Recurrence, Patient Counselling - [30]
Semash K, Dzhanbekov T. “Redefining the treatment paradigm for esophageal gastrointestinal stromal tumors: The emerging role of endoscopic resection.” World journal of gastroenterology (2025). PMID: 40599193 ↗
L3COHORTCited in: Detection of Recurrence - [31]
Ito N, Funasaka K, Furukawa K et al.. “Evaluation of the efficacy and safety of salvage photodynamic therapy with talaporfin sodium for lesions beyond those indicated for investigator-initiated clinical trials.” Esophagus : official journal of the Japan Esophageal Society (2025). PMID: 40517344 ↗
L4COHORTCited in: Detection of Recurrence - [32]
Fukuhara M, Urabe Y, Oka S et al.. “Endoscopic findings suggestive of a high risk of non-radical cure after definitive chemoradiotherapy for cT1bN0M0 esophageal squamous cell carcinoma.” Esophagus : official journal of the Japan Esophageal Society (2023). PMID: 37027046 ↗
L4COHORTCited in: Detection of Recurrence - [33]
Suzuki G, Yamazaki H, Aibe N et al.. “Chemoradiation versus surgery for superficial esophageal squamous cell carcinoma after noncurative endoscopic submucosal dissection: comparison of long-term oncologic outcomes.” Radiation oncology (London, England) (2022). PMID: 36401267 ↗
L3COHORTCited in: Detection of Recurrence - [34]
Nezu Y, Manabe N, Yoda Y et al.. “Effectiveness of screening endoscopy for esophageal squamous cell carcinoma in Japanese males.” United European gastroenterology journal (2022). PMID: 35976761 ↗
L3COHORTCited in: Detection of Recurrence - [35]
Lee BE, Kim GH, Shin N et al.. “Histopathological Analysis of Esophageal Mucosa in Patients with Achalasia.” Gut and liver (2021). PMID: 33361546 ↗
L4COHORTCited in: Detection of Recurrence - [36]
Depypere L, Thomas M, Moons J et al.. “Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.” World journal of surgical oncology (2019). PMID: 31133018 ↗
L4COHORTCited in: Detection of Recurrence - [37]
Furtado M, Davis D, Groarke JM et al.. “Experiences of informal caregivers supporting individuals with upper gastrointestinal cancers: a systematic review.” BMC health services research (2024). PMID: 39143501 ↗
L2SR_COHORTCited in: Late Toxicity and Survivorship - [38]
Anandavadivelan P, Wikman A, Malberg K et al.. “Prevalence and intensity of dumping symptoms and their association with health-related quality of life following surgery for oesophageal cancer.” Clinical nutrition (Edinburgh, Scotland) (2020). PMID: 32883547 ↗
L2PROSPECTIVE_COHORTCited in: Late Toxicity and Survivorship - [39]
St-Pierre J, Coca-Martinez M, Drummond K et al.. “Multimodal prehabilitation to enhance functional capacity of patients with esophageal cancer during concurrent neoadjuvant chemotherapies-a randomized feasibility trial.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2024). PMID: 39377252 ↗
L4RCTCited in: Late Toxicity and Survivorship - [40]
Fontes F, Fernandes D, Almeida A et al.. “Patient-Reported Outcomes after Surgical, Endoscopic, or Radiological Techniques for Nutritional Support in Esophageal Cancer Patients: A Systematic Review.” Current oncology (Toronto, Ont.) (2024). PMID: 39451764 ↗
L2SR_COHORTCited in: Late Toxicity and Survivorship - [41]
Do JH, Gelvosa MN, Choi KY et al.. “Effects of Multimodal Inpatient Rehabilitation vs Conventional Pulmonary Rehabilitation on Physical Recovery After Esophageal Cancer Surgery.” Archives of physical medicine and rehabilitation (2022). PMID: 35760108 ↗
L3COHORTCited in: Late Toxicity and Survivorship - [42]
Kissel M, Chirat E, Annede P et al.. “Esophageal brachytherapy: Institut Gustave Roussy's experience.” Brachytherapy (2020). PMID: 32444283 ↗
L4RETROSPECTIVE_COHORTCited in: Late Toxicity and Survivorship - [43]
Chen X, Zheng R, Xu X et al.. “Frailty and Health-Related Quality of Life in Elderly Patients Undergoing Esophageal Cancer Surgery: A Longitudinal Study.” Asian nursing research (2024). PMID: 38677471 ↗
L3COHORTCited in: Late Toxicity and Survivorship - [44]
Yano T, Yoda Y, Nonaka S et al.. “Pivotal trial of a biodegradable stent for patients with refractory benign esophageal stricture.” Esophagus : official journal of the Japan Esophageal Society (2022). PMID: 35106667 ↗
L2NON_RANDOMIZED_TRIALCited in: Late Toxicity and Survivorship - [45]
Hirpara DH, Kidane B, Rogalla P et al.. “Frailty assessment prior to thoracic surgery for lung or esophageal cancer: a feasibility study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018). PMID: 30426204 ↗
L4NON_RANDOMIZED_TRIALCited in: Late Toxicity and Survivorship - [46]
Marilina S, Adriana M, Anna S et al.. “Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map.” Journal of evidence-based medicine (2023). PMID: 37303304 ↗
L5NARRATIVE_REVIEWCited in: Late Toxicity and Survivorship - [47]
Himematsu H, Fukushima T, Matsumori K et al.. “Predictors of postoperative health-related quality of life in patients with esophageal cancer: a scoping review.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42424590 ↗
L5NARRATIVE_REVIEWCited in: Late Toxicity and Survivorship - [48]
Jezerskyte E, Saadeh LM, Hagens ERC et al.. “Long-Term Quality of Life Following Transthoracic and Transhiatal Esophagectomy for Esophageal Cancer.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2020). PMID: 32909195 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [49]
Jezerskyte E, Saadeh LM, Hagens ERC et al.. “Long-term health-related quality of life after McKeown and Ivor Lewis esophagectomy for esophageal carcinoma.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2020). PMID: 32444879 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [50]
Murphy CF, Fanning M, Raftery N et al.. “Early experience with a nutrition and survivorship clinic in esophageal cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2021). PMID: 32566939 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [51]
Cai Y, Zhao J, Li W et al.. “The effects of Managing Cancer and Living Meaningfully (CALM) on psychological distress in esophageal cancer patients.” Future oncology (London, England) (2023). PMID: 37469307 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [52]
Hamamoto Y, Inagawa A, Yamamoto T et al.. “A discrete choice experiment to assess treatment preferences for patients with esophageal cancer in Japan.” Esophagus : official journal of the Japan Esophageal Society (2025). PMID: 40690146 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [53]
Schuring N, Jezerskyte E, van Berge Henegouwen MI et al.. “Influence of postoperative complications following esophagectomy for cancer on quality of life: A European multicenter study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2022). PMID: 35987796 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [54]
Pucher PH, Coombes A, Evans O et al.. “Patient perspectives on key symptoms and preferences for follow-up after upper gastro-intestinal cancer surgery.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022). PMID: 35275293 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [55]
Trottenberg T, Hegazy M, Astany S et al.. “Esophageal Cancer Patient Network: a scalable platform for integrating patient voices across the research lifecycle.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42119036 ↗
L5OTHERCited in: Late Toxicity and Survivorship - [56]
Kohn GP, Litle V, Eliya Y et al.. “ISDE guidelines on the management of cT2N0 esophageal cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 41785274 ↗
L1GUIDELINECited in: Patient Counselling - [57]
Yasuda T, Matsuda A, Hagiwara N et al.. “Rethinking Perioperative Corticosteroids in Esophageal Cancer Surgery: Evidence From an Integrative Meta-Analysis.” Annals of gastroenterological surgery (2026). PMID: 42395126 ↗
L1SR_MA_RCTCited in: Patient Counselling - [58]
Zhu Y, Qi X, Ni S et al.. “First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison.” Biologics : targets & therapy (2026). PMID: 41788456 ↗
L1SR_MA_RCTCited in: Patient Counselling - [59]
de Oliveira JF, Martins BC, Moura RN et al.. “Randomized trial of intralesional steroid injection versus oral prednisolone for preventing esophageal stricture after extensive endoscopic submucosal dissection.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 41926323 ↗
L1RCTCited in: Patient Counselling - [60]
Jiang W, Huang Y, Pang J et al.. “Diagnostic accuracy of magnifying Image-enhanced endoscopy for predicting the invasion depth of superficial esophageal neoplasm: a meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42097052 ↗
L2SR_COHORTCited in: Patient Counselling - [61]
Sanders ME, van der Horst S, Weijs TJ et al.. “Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42043275 ↗
L2PROSPECTIVE_COHORTCited in: Patient Counselling - [62]
Deuning-Smit E, Vos JAM, Motazedi E et al.. “Longitudinal health-related quality of life profiles in esophageal cancer: insights from a nationwide prospective observational cohort study.” Journal of cancer survivorship : research and practice (2026). PMID: 41555149 ↗
L2PROSPECTIVE_COHORTCited in: Patient Counselling - [63]
Iden CR, Øgaard N, Mustafa SM et al.. “Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 42176235 ↗
L2NON_RANDOMIZED_TRIALCited in: Patient Counselling - [64]
Harada T, Sato H, Okura K et al.. “Preoperative risk factors for postoperative pneumonia in patients with esophageal cancer: A systematic review and meta-analysis.” Surgery today (2026). PMID: 42234145 ↗
L2SR_COHORTCited in: Patient Counselling - [65]
Ikeda T, Noma K, Okura K et al.. “Preoperative exercise capacity as a predictor of postoperative pulmonary complications in patients with esophageal cancer: a multicenter observational cohort study.” Esophagus : official journal of the Japan Esophageal Society (2026). PMID: 42380723 ↗
L3RETROSPECTIVE_COHORTCited in: Patient Counselling - [66]
Xue Z, Beijia L, Qin X et al.. “Clinical predictors of early reflux and symptom severity after esophagectomy: a risk prediction tool.” Esophagus : official journal of the Japan Esophageal Society (2026). PMID: 42380722 ↗
L3RETROSPECTIVE_COHORTCited in: Patient Counselling - [67]
Kosumi K, Harada K, Shimogawa T et al.. “Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study.” Annals of surgical oncology (2026). PMID: 42201494 ↗
L3COHORTCited in: Patient Counselling - [68]
Yoshida M, Urabe Y, Kadota T et al.. “Size and Macroscopic Type of Type B2 Vessel Areas in JES Classification for Predicting Invasion Depth: A Multicenter Prospective Study.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 42144869 ↗
L3COHORTCited in: Patient Counselling - [69]
Wu F, Luo C, Zhou S et al.. “Recurrent laryngeal nerve lymph nodes status prediction after neoadjuvant therapy for thoracic esophageal squamous cell carcinoma.” Insights into imaging (2026). PMID: 41945240 ↗
L3RETROSPECTIVE_COHORTCited in: Patient Counselling